Oral administration of an Myc inhibitor can significantly reduce KIM-1 expression, which is a sensitive indicator of renal tubular injury, the accumulation of inflammation in mice, and fibrosis, while ultimately slowing the progression of AKI to CKD (Lemos et al., 2018). Here, HAVCR1 is linked to chronic kidney disease.